1 Feb 2024 • A recent study in Brazil found that a single dose of a live, attenuated, tetravalent dengue vaccine i.e the Butantan–Dengue Vaccine (Butantan-DV), prevented symptomatic disease regardless of baseline serostatus.

Over a 2 year period, the vaccine's efficacy varied based on previous dengue exposure, showcasing an efficacy of 73.6% in preventing symptomatic DENV types 1 and 2 in participants with no prior exposure and an even higher 89.2% in those with a history of exposure.

Notably, efficacy was pronounced across age groups, with rates of 80.1% for 2 to 6-year-olds, 77.8% for 7 to 17-year-olds, and an impressive 90.0% for those aged 18 to 59 years.

Source: NEJM | Read full story